Switzerland EXPERTS TAKING CARE

Similar documents
BRUSSELS CORDENPHARMA EXPERTS TAKING CARE

CORDENPHARMA BRUSSELS EXPERTS TAKING CARE

Best-in-class API / HPAPI / Small Molecules Custom Manufacturing

GLOBAL SUPPORT FOR A QUALITY SOLUTION

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Table of Contents. Welcome to Dishman. Our Mission. Our Focus: Client Satisfaction

Lonza Nansha, China For Global Excellence in Advanced Chemical Synthesis

COMPANY PROFILE. Dishman offers innovation, security of supply and value for money. Dishman Group. Research EARLY STAGE API. Preclinical.

The Complete Solution: Althea s Simplified ADC Supply Chain

PHARMACEUTICAL TESTING

Stellence Pharmscience Pvt Ltd. 456, Road #3, Industrial Area, Jigani, Bangalore South,

3M Drug Delivery Systems. April 26, 2011

Exclusive Manufacturing Solutions

PRAXIS. A publication by Bioengineering AG

CelaSYS Customized PEGylation Solutions BOS CMC Copenhagen c e l a r e s gmbh Slide 1

Proquina A Bayer Company

Proquina A Bayer Company

PLANKSTADT EXPERTS TAKING CARE

Jubilant Life Sciences Ltd. with its strong Medicinal, Synthetic, Organic Chemistry and

Novartis Business Services HR University Relations. Chemical and Analytical Development. Early Talent Program

MDI Manufacturing Services

CHINOIN PROFESSIONAL RELIABLE DEDICATED PROSTAGLANDIN EXPERTISE

Pharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148

Jefferies 2018 Global Healthcare Conference. June 7, 2018

Formulation Development & CTM Manufacturing Services

We make drugs smarter

Validation of Pharmaceutical Manufacturing Process Focus: APIs.

in full-service contract pharmaceutical development and manufacturing

Evonik Birmingham Laboratories

FROM CLINICAL TO COMMERCIAL CUSTOM CAN. An overview of our Development and Manufacturing capabilities

Vetter Development Service

News Release. Even more attractive to life science and fine chemical industries. Saltigo at CPhI 2017, Frankfurt, October 24-26, 2017, Stand 111H21

Preparative / Process

The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to

Corporate. Established in Acquired facilities of: Competencies across the Generics & Biologics, value chain.

Strategies for IND Filing Success: Chemistry, Manufacturing and Controls

Introduction to CMC Regulatory Affairs

Almac Sciences. API Services and Chemical Development: your molecule, our expertise

ICH Q11 Development & manufacture of drug substances

Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach

Manufacturers of. Pharmaceutical Formulations Active Pharmaceutical Ingredients Drug Intermediates ULTRATECH INDIA LIMITED

Business Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs

Company Overview and Products & Services

Pharma&Biotech. ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful

Analysis of Protein Biopharmaceuticals

CU Chemie Uetikon GmbH

Overview Rentschler Biotechnologie

CUSTOM PEPTIDE SYNTHESIS AT BACHEM

Laboratory Services Alcami s comprehensive development and testing services are well established and ready to assist your pharmaceutical product

Vetter Development Service

IMPURITIES IN NEW DRUG PRODUCTS

catalogue Key Organics Chemistry Innovation Quality

How to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER

Cooperation in the field of toxicology, analytics, R&D and production

European Medicines Agency Evaluation of Medicines for Human Use

Cleaning and Cleaning Validation of API Plant and Equipment

Regulatory Issues and Drug Product Approval for Biopharmaceuticals

Development and Scale up in API Manufacture (Part 2 Quality Assurance Considerations)

Intertek Melbourn Company Presentation. MIBio 2016

API Testing Requirements to Support the EI Risk Assessment. Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016

At LATITUDE, we only do one thing, and we do it very well.

CMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C.

Profile for Pharma Formulation and Synthesis. Together!

Elemental impurities impact on APIs

Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry

Finding the right partner for preclinical into phase I. Facts, Threats & Opportunities

Examples of regulatory expectations for analytical characterization and testing

ASCENDIA PHARMACEUTICALS Aspiring for Better Medicine

ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances

Development. - Be Your Partner-

Contract Manufacturing Services for Pre-filled Syringes

CREATING TOMORROW S SOLUTIONS BIOPHARMACEUTICALS I CONTRACT MANUFACTURING WACKER BIOTECH: THE MICROBIAL CMO

About Us. What We Do and Who We Are. Company. Management

CV Mads Friis Sørensen, Elsdyrvej 18, 4623 Lille Skensved

Thermo Scientific Nucleic Acid Technologies

Jefferies 2017 Global Healthcare Conference. June 7, 2017

Impurities from degradation of Drug Substances

MARKETS & CUSTOMERS. Progressing globalization. Evolving markets

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance

Regulatory Review Considerations of Drug-Linker Quality in ADCs

Anushri Global Pharma Consultants

Stephens Fall Investment Conference

Starting Material Selection for Type II Drug Master Files

UNLEASH THE POWER OF PRECISION MEDICINE

Drug-Device Combination Product Development: INDs for Device Companies

Synthesis to Clinic 14 C studies in man a Chemistry. Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013

Custom Oligonucleotide Synthesis & Products. The Modified Nucleic Acid Experts

VICH Topic GL10. Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN NEW VETERINARY DRUG SUBSTANCES

CHAPTER 1 INTRODUCTION

Regulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA

Vetter Commercial Manufacturing

Pharmaceutical Sciences

CONTRACTING CELL CULTURE

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON SUMMARY OF REQUIREMENTS FOR ACTIVE SUBSTANCES IN PART II OF THE DOSSIER

Your partner in the pharmaceutical industry

Regulatory Starting Materials An FDA Perspective

Biotechpharma company profile. Romanas Ramanauskas Business development manager

Design and Implementation of a Small Footprint Continuous API facility for Portfolio Commercialization. Eoin McManus Eli Lilly and Company March 2016

Antibody Drug Conjugates - Introduction to a new EBE initiative EBE Satellite Session Paris - May 9, 2016

Recent Opportunities & Challenges in microbial manufacturing

Transcription:

CordenPharma Switzerland EXPERTS TAKING CARE CordenPharma Switzerland Eichenweg 1 4410 Liestal Switzerland Phone +41 61 906 59 59 Fax +41 61 906 59 58 sales@cordenpharma.com www.cordenpharma.com

Our History 1987 - Founded as Sygena AG focusing on lipid and amino acid chemistry 1994 - Genzyme Corporation acquired Sygena AG for the GMP manufacture of APIs and high-value pharmaceutical excipients 1999 - Sygena officially changed its name to Genzyme Pharmaceuticals 2011 - Genzyme Pharmaceuticals acquired by ICIG to become CordenPharma Switzerland cordenpharma Switzerland CordenPharma Switzerland, located in Liestal near Basel, is a cgmp manufacturing facility with over 25 years of experience in the production of pharmaceutical ingredients including synthetic lipids, peptides, carbohydrates and other complex small molecules. CordenPharma Switzerland is additionally an industry-recognized leader in the manufacturing of amino acid derivatives and pseudoproline dipeptides suitable for the GMP production of Your CMO Partner > 25 Years of Experience peptide APIs. CordenPharma Switzerland s chemists are experts in developing and providing scalable processes, analytical controls and full DMF / IND / IMPD support for the manufacture of complex molecules. us Compliance Worldwide cgmp certification - API manufacturing and Analytical Testing US-FDA 2000, 2004, 2007, 2011 Swissmedic bi-annually - most recently April 2011, April 2013 Numerous customers from all over the world

what we do Custom Manufacturing of APIs Lipids, Peptides & Carbohydrates CordenPharma Switzerland is the leader in the production of fully synthetic glycero and sphingolipids, which are highly purified single compounds produced in bulk quantities with consistent batch-to-batch quality. Used as critical formulation excipients and APIs in a number of approved parenterals and pulmonary delivered therapeutics, our lipids are available in small quantities for Research & Development. CordenPharma Switzerland is also a preferred partner for the custom manufacture of cationic lipids used in liposomal delivery of oligonucleotide-based active ingredients. Our core competencies furthermore include solution-phase and/or solid-phase peptide chemistry. With in-house development and multi-ton production capabilities for chiral building blocks, unusual and natural amino acid derivatives, our cost-effective peptide API manufacturing ensures the best possible control of supply chain and regulatory requirements. In addition, we pioneered the production and use of pseudoproline dipeptides building blocks, which are powerful tools for bypassing challenges associated with the synthesis of difficult sequences and long peptides. CordenPharma Switzerland has additionally developed expertise in the efficient manufacture of carbohydrates (mono- and oligosaccharide building blocks and chemically-defined glycans) on a multi-kg scale. Combined with our strong expertise in fully-synthetic lipid, peptide and amino acid chemistry, CordenPharma Switzerland is uniquely positioned to manufacture glycoconjugates such as glycosyl amino-acids, glycopeptides or glycolipids. Our Swiss facility maintains an independent Quality Assurance group and Quality Control laboratories, ensuring seamless customer support in critical development areas such as analytical development & validation, cleaning method development & validation, stability studies and the filing and maintenance of documentation such as US-DMFs, EDMFs and others. Core Capabilities Synthetic Phospholipids Peptides Conjugates Carbohydrates Small Molecules Proprietary Building Blocks (small pack) - Synthetic Phospholipids - AADs - Pseudoproline Dipeptides We serve an expansive global customer base from start-up to large biotech or pharma with complex development and commercial products, R&D samples and reference standards in various stages.

Technologies / Processes In addition to lipid, peptide and carbohydrate chemistry, CordenPharma Switzerland has proven scale-up experience in a broad range of chemical transformations including but not limited to: Acetylation Acylation Enantioselective synthesis Catalytic Hydrogenation (homogeneous, heterogeneous) Suzuki Coupling Sharpless Epoxidation Grignard reaction Mitsunobu reaction Organometallic reactions Phosphorylation Polymerisation Oxidation (Swern/Tempo) Wittig reaction Equipment Details Equipment for pilot batches and commercial production Kilo-lab suites for small-scale cgmp requirements Equipment capacity ranging from 20 to 160 L Reactor suites - Reactor capacity: 60 to 2500 L - Temperature range: -90 C to 160 C Drying suites - Conical dryer - Vacuum tray dryers Milling/Screening suite Large-scale chromatography CMC Development cgmp Manufacture Experienced project managers for seamless technology transfer, route scouting and process development for exclusive NCEs, excipients and high-value intermediates Manufacturing process validation studies Clinical trial and commercial material supply Analytical Support Analytical method development and validation for in-process and release testing Impurity profile characterization Reference standard production, qualification and supply to customers Cleaning method development & validation Quality & Regulatory Support Stability testing according to ICH guidelines Forced degradation studies Filing and maintenance of US-DMFs, EDMFs and others Authoring of response dossiers to authorities Specialized Purification & Isolation Equipment Preparative HPLC equipment (reversed phase; normal phase) Lyophilization Capacities Reaction vessels (multi-purpose and dedicated equipment) Pilot plant for kg-scale cgmp production in vessel volumes ranging from 20 L to 2500 L